Cargando…

Splicing factor proline- and glutamine-rich regulates cytotoxic T lymphocytes-mediated cytotoxicity on non-small cell lung cancer by directly binding to PD-L1 3’UTR

Splicing factor proline- and glutamine-rich (SFPQ) can interact with RNAs to regulate gene expression. The function of SFPQ in the immunotherapy of non-small cell lung cancer (NSCLC) is investigated in this study. H1299 and A549 cells were transfected with shSFPQ plasmid. Cell counting kit-8 (CCK-8)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Yanming, Cheng, Yongxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637510/ https://www.ncbi.nlm.nih.gov/pubmed/37960731 http://dx.doi.org/10.1097/MD.0000000000035837

Ejemplares similares

The Splicing Factor Proline-Glutamine Rich (SFPQ/PSF) Is Involved in Influenza Virus Transcription
por: Landeras-Bueno, Sara, et al.
Publicado: (2011)

Association of cytotoxic T lymphocyte-associated protein 4 gene -1772T/C polymorphism with gastric cancer risk: A prisma-compliant meta-analysis
por: Zhuo, Chenyi, et al.
Publicado: (2020)

Cyclosporin-A reduced the cytotoxicity of propranolol in HUVECs via p38 MAPK signaling
por: Lv, Zhong, et al.
Publicado: (2022)

Arginine methylation and citrullination of splicing factor proline- and glutamine-rich (SFPQ/PSF) regulates its association with mRNA
por: Snijders, Ambrosius P., et al.
Publicado: (2015)

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer
por: Anzai, Masaki, et al.
Publicado: (2017)

Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity
por: Pellarin, Ilenia, et al.
Publicado: (2020)

Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in non-small cell lung cancer
por: Bayraktaroglu, Mesut, et al.
Publicado: (2023)

Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors
por: Li, Lingling, et al.
Publicado: (2021)

Direct Microbicidal Activity of Cytotoxic T-Lymphocytes
por: Oykhman, Paul, et al.
Publicado: (2010)

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
por: Zhao, Yanjie, et al.
Publicado: (2020)

The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis
por: Wu, Lin-guang-jin, et al.
Publicado: (2021)

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy
por: Kutlu, Yasin, et al.
Publicado: (2023)

Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer: A Meta-Analysis
por: Zhang, Yaxiong, et al.
Publicado: (2015)

Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer
por: Zhang, Yan, et al.
Publicado: (2018)

Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer
por: Zhao, Guanghui, et al.
Publicado: (2020)

Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity
por: Bhat, Purnima, et al.
Publicado: (2017)

Effect of human secretory calcium-binding phosphoprotein proline-glutamine rich 1 protein on Porphyromonasgingivalis and identification of its active portions
por: Mary, Charline, et al.
Publicado: (2021)

A real-world study of recombinant human endostatin combined with PD-1/PD-L1 blockade and chemotherapy for patients with advanced non-small cell lung cancer negative for actionable molecular biomarkers
por: Zhao, Jing-Wen, et al.
Publicado: (2023)

Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis
por: Xu, Jun, et al.
Publicado: (2021)

A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
por: Wang, Cuihua, et al.
Publicado: (2016)

Lymphocyte-activating gene-3 expression is associated with tumor-infiltrating lymphocyte levels in HER2-positive breast cancers
por: Lee, Seokwon, et al.
Publicado: (2021)

Correlation between neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and postoperative cognitive dysfunction in elderly patients with esophageal cancer
por: Zhao, Jie, et al.
Publicado: (2023)

Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials
por: Zhou, Guo-Wu, et al.
Publicado: (2016)

Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis
por: Zheng, Zheng, et al.
Publicado: (2020)

Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report
por: Yamaguchi, Kyoko, et al.
Publicado: (2021)

High neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predict poor survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy
por: Ke, Te-Min, et al.
Publicado: (2020)

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
por: Hao, Chunyan, et al.
Publicado: (2017)

Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis
por: Wang, Qianqian, et al.
Publicado: (2017)

Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials
por: Zhu, Peng, et al.
Publicado: (2021)

Peripheral platelet/lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil: Lymphocyte
por: Chen, Liang, et al.
Publicado: (2016)

Impact of radiotherapy on circulating lymphocyte subsets in patients with esophageal cancer
por: Lv, Yajuan, et al.
Publicado: (2020)

A novel risk signature with 6 RNA binding proteins for prognosis prediction in patients with glioblastoma
por: Huang, Qian-Rong, et al.
Publicado: (2021)

Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports
por: Lu, Chieh-Sheng, et al.
Publicado: (2017)

Pathological pseudoprogression to anti-PD-1 inhibitor in metastatic periampullary carcinoma: Case report
por: Wang, Junhui, et al.
Publicado: (2023)

The co-expression of CBX8 and PD-L1 and prognostic value in cervical cancer
por: Zhou, Hui, et al.
Publicado: (2021)

Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer
por: Huang, Qing, et al.
Publicado: (2020)

The value of hemoglobin-to-red blood cell distribution width ratio (Hb/RDW), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) for the diagnosis of nasopharyngeal cancer
por: Lin, Zhongyuan, et al.
Publicado: (2021)

Higher neutrophil-lymphocyte ratio is associated with better prognosis of hepatocellular carcinoma
por: Li, Sheng-chao, et al.
Publicado: (2020)

Cutoff point of neutrophil-to-lymphocyte ratio for predicting survival in nasopharyngeal carcinoma
por: Setakornnukul, Jiraporn, et al.
Publicado: (2021)

Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab: A case report
por: Misir Krpan, Ana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cd9sa3luqbmcmvc290n1ht3qul